Categories Earnings, Technology

Garmin (GRMN) exceeds Q4 2019 estimates; guides above view

Shares of Garmin (NASDAQ: GRMN) rose about 8% during pre-market trading on Wednesday after the wearable tech firm reported yet another market-beating quarterly results for Q4 and provided upbeat outlook for FY20.

Garmin’s adjusted EPS grew 26% to $1.29 in the fourth quarter of 2019 exceeding the Street’s view of $1.04. Revenue increased 18% to $1.10 billion compared to the analysts’ target of $1.01 billion.

Garmin (GRMN) exceeds Q4 2019 earnings, revenue estimates; FY20 guidance above market views

GAAP profit increased to $1.89 per share from a profit of $1.00 per share in the prior-year quarter. Except Auto, all the other segments registered revenue growth in the three months ended December 28, 2019 period. The introduction of new products in the fourth quarter benefited the company resulting in solid revenue growth across all the segments.

Revenue of Fitness, Aviation, Marine, and Outdoor segments grew 34%, 22%, 22% and 16%, respectively. Auto segment revenue declined 15% due to the ongoing PND market contraction and lower year-over-year OEM sales.

For fiscal 2020, Garmin expects adjusted EPS of $4.60 on revenue of about $4 billion. Wall Street had expected the company to forecast earnings of $4.34 per share and revenue of $3.84 billion.

Read: Garmin third quarter 2019 earnings transcript

“2019 was another exciting year of growth thanks to our strong lineup of products and unique innovations. We entered 2020 with a great lineup of recently introduced products with more on the way,” said CEO Cliff Pemble.

The company lifted its annual dividend by 7% to $2.44 a share from $2.28 a share. GRMN stock was broadly unchanged in the past three months and had gained 36% from this time last year.

Get access to timely and accurate verbatim transcripts that are published within hours of the event

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top